Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Renal Cell 46Sarcoma 21Neoplasms 18Neoplasm Metastasis 15Ovarian Neoplasms 12Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 8Recurrence 5Melanoma 5Fallopian Tube Neoplasms 5Thyroid Neoplasms 4Prostatic Neoplasms 4Liposarcoma 4Hemangiosarcoma 4Urinary Bladder Neoplasms 3Solid Tumors 3Lung Neoplasms 3Leiomyosarcoma 3Kidney Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Ovarian Epithelial 3Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Refractory Solid Tumors 2Neuroendocrine Tumors 2Gliosarcoma 2Financial Stress 2Chondrosarcoma, Extraskeletal Myxoid 2

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrent Uterine Corpus Sarcoma × pazopanib × Clear all
NCT01247571 2019-08-08

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 8 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡